ProfileGDS5678 / 1428971_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 93% 93% 93% 93% 92% 93% 92% 94% 95% 95% 94% 94% 94% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.0210194
GSM967853U87-EV human glioblastoma xenograft - Control 27.9652993
GSM967854U87-EV human glioblastoma xenograft - Control 38.036593
GSM967855U87-EV human glioblastoma xenograft - Control 48.1222593
GSM967856U87-EV human glioblastoma xenograft - Control 58.036393
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.4249992
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.6905493
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.6630192
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.9859794
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.3083795
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.3647795
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.3037394
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.237694
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.1542294